Swapna Thota, MD Swapna Thota, MD

Swapna Thota

Hematologic Oncology

Specializing In:

Acute leukemias Myeloproliferative neoplasms Myelodysplastic syndrome Aplastic anemia/ PNH Acquired bone marrow failure conditions

Special Interests:

Myeloproliferative syndromes Myelodysplastic syndromes Molecular biology of myeloid malignancies

About Swapna Thota


I joined Roswell Park in 2017. I specialize in taking care of patients with acute leukemias, myelodysplastic syndromes and other blood cancers. I completed my residency at Fairview hospital, Cleveland and fellowship training at Cleveland Clinic's Taussig Cancer Institute. I am board certified in Internal Medicine and board eligible for Hematology/Medical Oncology. I am also a member of multiple professional organizations including American Society of Clinical Oncology, American Society of Hematology and American College of Physicians.

In terms of my research, as a clinical investigator trained with a specific focus in hematologic malignancies, I am interested in novel drug development to improve outcomes in patients with blood cancers. Specifically, I investigate biomarker-driven or modern targeted therapies for treating hematologic malignancies. I hope to translate novel findings from the lab to the patients by conducting early phase clinical trials.


Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Department of Medicine
Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo
  • Assistant Professor of Medicine


Education and Training:

  • MD - Osmania Medical College, India


  • Internal Medicine, Cleveland Clinic, Fairview


  • Experimental Therapeutic (MDS/Leukemia) - Cleveland Clinic, Taussig Cancer Institute
  • Hematology & Oncology - Cleveland Clinic, Taussig Cancer Institute

Board Certification:

  • Internal Medicine

Professional Memberships:

  • 2013-Present - American Society of Hematology (ASH)
  • 2013-Present - American Society of Clinical Oncology (ASCO)
  • 2010-Present - American College of Physicians (ACP)

Honors & Awards:

  • 2016 - Selected for AACR/ASCO Methods In Clinical Cancer Research Workshop: “ A Phase II trial of single agent metformin in TET2 mutated low risk MDS patients”
  • 2014 - Awarded Clinical Excellence in MDS from Edward P. Evan’s MDS Clinical Research Consortium for successful completion of MDS/Leukemia research fellowship and for translational research conducted.
  • 2014 - Abstract Achievement Award from American Society of Hematology
  • 2013 - Abstract Achievement Award from American Society of Hematology for two oral presentations
  • 2013 - Best Abstract Award for oral presentation on “ Outcomes of small cell carcinoma of urinary bladder - a Cleveland Clinic experience” Department of Internal Medicine, Fairview- Cleveland Clinic
  • 2012 - Caregiver Celebration Award, for excellence in clinical care from Cleveland Clinic
  • 2011 - Awarded American College of Physicians Merit Award and selected as Poster Finalist
  • 2011 - Caregiver Celebration Award, for excellence in clinical care from Cleveland Clinic


Full Publications list on PubMed
  • Bilori B, Thota S, Clemente MJ, Patel B, Jerez A, Afable Ii M, Maciejewski JP. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia. Leukemia. 2015 Dec;29(12):2427-9. doi: 10.1038/leu.2015.280. Epub 2015 Oct 9. PMID: 26449659.
  • Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B, Sekeres MA, Levine RL, Maciejewski JP. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood. 2014 Sep 11;124(11):1790-8. doi: 10.1182/blood-2014-04-567057. Epub 2014 Jul 8. PMID: 25006131; PMCID: PMC4162108.
  • Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Przychodzen B, Hirsh C, Viny AD, Hosano N, Bleeker FE, Meggendorfer M, Alpermann T, Shiraishi Y, Chiba K, Tanaka H, van Noorden CJ, Radivoyevitch T, Carraway HE, Makishima H, Miyano S, Sekeres MA, Ogawa S, Haferlach T, Maciejewski JP. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. 2015 Nov;29(11):2134-42. doi: 10.1038/leu.2015.91. Epub 2015 Apr 3. PMID: 25836588; PMCID: PMC5821256.
  • Thota S, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2017 May;98(5):425-434. doi: 10.1111/ejh.12862. Epub 2017 Mar 9. Review. PMID: 28152223.
  • Thota S, Patel BJ, Sadaps M, Balasubramanian S, Sanikommu S, Hirsch C, Marotta S, Sekeres MA, Risitano AM, Maciejewski JP. Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. Br J Haematol. 2018 Oct;183(1):133-136. doi: 10.1111/bjh.14907. Epub 2017 Sep 14. PMID: 28905372.

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment

See what others are saying about Swapna Thota, MD, and leave your own review.

Leave a Review